European HIV Vaccine Alliance is a large integrated research project funded by the European Union H2020 program
European HIV Vaccine Alliance (EHVA) is a large consortium funded by the European Union Horizon 2020 program. EHVA brings together 39 partners from 11 countries in Europe, 4 in Sub-Sahara Africa and the US. Its primary objectives are to develop and implement:
1) Discovery Platform with the goal of generating novel vaccine candidates inducing potent neutralizing and non-neutralizing antibody responses and T-cell responses;
2) Immune Profiling Platform with the goal of ranking novel and existing (benchmark) vaccine candidates on the basis of the immune profile;
3) Data Management/Integration/Down-Selection Platform, with the goal of providing statistical tools for the analysis and interpretation of complex data and algorithms for the efficient selection of vaccines;
4) Clinical Trials Platform with the goal of accelerating the clinical development of novel vaccines and the early prediction of vaccine failure.
EHVA is coordinated by the Institute National de la Santé et de la Recherche Médicale (INSERM) and the scientific leadership is carried out conjointly with the Lausanne University Hospital (CHUV). EVF provides the scientific project management support to the program.
For more information, please see: www.ehv-a.eu